ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
28.75
+0.01 (0.02%)
Nov 27, 2024, 12:03 PM EST - Market open

ArriVent BioPharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
14.879.716.473.02
Research & Development
78.8564.8830.438.58
Operating Expenses
93.7274.5936.9111.59
Operating Income
-93.72-74.59-36.91-11.59
Interest & Investment Income
12.675.26--
EBT Excluding Unusual Items
-81.05-69.33-36.91-11.59
Pretax Income
-81.05-69.33-36.91-68.81
Net Income
-81.05-69.33-36.91-68.81
Net Income to Common
-81.05-69.33-36.91-68.81
Shares Outstanding (Basic)
24211
Shares Outstanding (Diluted)
24211
Shares Change (YoY)
1230.98%67.64%79.57%-
EPS (Basic)
-3.42-32.38-28.90-96.75
EPS (Diluted)
-3.42-32.38-28.90-96.75
Free Cash Flow
-68.97-55.84-43.63-16.78
Free Cash Flow Per Share
-2.91-26.08-34.16-23.60
EBIT
-93.72-74.59-36.91-11.59
Source: S&P Capital IQ. Standard template. Financial Sources.